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INTRODUCTION 
Hematological abnormalities contribute to the morbidity and mortality asso-
ciated with HIV and AIDS, that they hinder the treatment directed at HIV and 
the opportunistic infections and malignancies of AIDS. These would augment 
the risk of bacterial infection and affect the quality of life. Hence this study is 
designed to find out the spectrum of hematological abnormalities in HIV pa-
tients and their correlation with absolute CD4 count and HIV (RNA) viral load. 
This would be a cross sectional study among 100 HIV patients getting treat-
ment at a tertiary care hospital. This study would show the prevalence of ane-
mia, neutropenia and thrombocytopenia and their association with immune 
suppression. 
A variety of hematological manifestations are seen at every stage of human 
immunodeficiency virus infection /acquired immunodeficiency syndrome and 
they often pose a great challenge in the comprehensive management. Hemato-
logical abnormalities and their complications are the most common cause of 
mortality and morbidity in HIV infected individuals. 
Anaemia is the commonest hematological abnormality associated with HIV in-
fection and anaemia is present in about 10-20% HIV infected patients at diag-
nosis, and their prevalence can range from 66-85% during disease 
course.Neutropenia occurs in 10-30% of individuals affected with HIV infec-
tion, typically in those with advanced disease stages. Thrombocytopenia has 
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been seen in 3-40% of individuals and it may be the initial presentation, and 
can occur at any stage of the disease.  
Anemia and neutropenia are mostly because of inadequate production due to 
suppression of bone marrow by HIV infection .This occurs because of abnor-
mal cytokine expression and alteration in bone marrow micro environ-
ment.Whereas thrombocytopenia occurs by immune-mediated destruction of 
the platelets, in addition to inadequate platelet production. Other causes of cy-
topenia in these patients include treatment-related adverse events or secondary 
to the opportunistic infections or neoplasms, or preexisting or coexisting medi-
cal issues. HIV infected patients with cytopenia require bone marrow examina-
tion to determine the cause of cytopenia and also to direct appropriate therapy.  
The severity of cytopenia and their incidence are usually correlated to the stage 
of the disease. These manifestations also reflect the underlying immune status 
if interpreted cautiously, especially if the patient is in regular follow-up.  
Hematological abnormalities can be the initial presentation of HIV infection. 
Patients may be asymptomatic, because of abnormal blood counts or lymphoid 
disorders, usually they were referred. By considering the possibility of HIV in-
fection, have the opportunity to diagnose and treat the patients earlier and pre-
vent transmission of the infection. Hematological abnormalities may be the di-
rect result of HIV infection or manifestations of secondary infections, neop-
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lasms or side effects of the therapy. It is necessary to identify and treat for he-
matological abnormalities to reduce the morbidity and mortality. 
Though many studies have been conducted in India on HIV manifestations, in 
most of them, various aspects were addressed and the focus on the hematologi-
cal manifestations were limited. Most of the available data is from the west, 
which might not be directly   applicable to our Indian population. This study 
was planned, since there is paucity of   information from Indian population re-
garding the hematological manifestation.  
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AIM 
Primary objective:  
To study the spectrum of hematological abnormalities in HIV infected 
patients 
Secondary objective:  
To find the correlation of hematological abnormalities with absolute 
CD4 count and HIV viral load 
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MATERIALS AND METHODS 
INCLUSION CRITERIA:  
 Age above 18 years 
 HIV infection confirmed by western blot or ELISA method 
 Patient giving consent for the study 
 Patients as both inpatient or outpatient 
EXCLUSION CRITERIA:  
 Patient refusing consent 
 Incomplete investigations 
STUDY DESIGN:  Observational  study 
STUDY LOCATION: PSG Hospitals, Coimbatore. 
SAMPLE SIZE: 100 
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The hematological protocol followed in the study is given below: 
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REVIEW OF LITERATURE 
HIV viral load and absolute CD 4 count are the most essential biomarkers cor-
relating to the stage of HIV disease and its progression (1)(2).These tests 
though they are important biomarkers , they are costlier . Hence there is diffi-
culty in doing these tests in HIV infected patients in developing countries .In 
HIV patients cytopenias are commonly noted (3)(4).Various hematological ab-
normalities are noted in every stage of HIV infection and they are of  big chal-
lenge for effective management . 
 For the sake of economical evaluation of the status of  HIV disease stage and 
its        progression, complete blood counts and peripheral smear has been sug-
gested as the      alternatives(5). It is found that low haemoglobin count is most 
common among HIV    patients and it is the most common finding among pa-
tients on HAART therapy (6)(7) . Low haemoglobin levels were also found to 
correlate with increased severity of the disease and poor prognosis 
(8)(5)(9)(10).Normocytic normochromic anaemia is the common finding 
among the blood picture of HIV patients. (11) Reasons for anaemia was found 
to be a) decreased production because of associated infections ,ART drugs ,low 
erythropoietin levels or HIV infection per se ; b) RBC lysis due to autoimmune 
hemolytic anaemia ,DIC or thrombotic microangiopathy ; c) Nutritional defi-
ciencies (12) . Neutropenia is also found in majority of patients with high viral 
load and low CD4 count (13) .Thrombocytopenia were noted during early stag-
es of the disease and it was not associated with poor prognosis. Thrombocyto-
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penia in HIV infection is due to immune complex mediated peripheral destruc-
tion and antiplatelet antibodies. Abnormalities in the bone marrow are noted at 
various stages of the HIV disease and more during later stage of the dis-
ease.HIV infection in the mesenchymal stem cells of marrow leads on to the 
various bone marrow abnormalities (14). HIV infection  leads on to a histiocyt-
ic reaction and further resulting in hemophagocytic syndrome .This causes se-
vere pancytopenia.HIV also causes decrease in progenitor cells in the bone 
marrow (15). 
As per Paradela A et al study, they have noted bone marrowdefects in HIV in-
fected individuals mainly showing features of increased cell counts, granulo-
matous changes and some amount of dysplasias (16). Studies conducted in vi-
tro has shown direct influence of HIV on  mesenchymal cells and hematopoie-
tic cell activity (14). 
Cytopenias are the leading cause of morbidity and mortality in HIV patients. 
Studies done world-wide says, the prevalence of anaemia in HIV infected per-
sons has been found to be as high as 63% to 95%, they also say that anaemia is 
more common than thrombocytopenia or leukopenia . In a US based study, 
Mildvan et al noted the  prevalence of  mainly anaemia in 9690 HIV infected 
individuals, and showed 39.5% (1721) of patient receiving no antiretroviral 
therapy and 35.5% (7252) of patients receiving HAART were anemic. They 
found anemia was more prevalent among men and patients with CD4<200 
cells/mm3 (17)
.
 Hematological manifestations also reflect the underlying im-
9 | P a g e  
 
mune status if interpreted cautiously, especially if the patient is in regular fol-
low-up. Volberding et al reported that more severe degree of anaemia were 
found among HIV infected individuals presenting with low CD4 counts (18) 
Among leucopenia, neutropenia is more prevalent in HIV patients. Its preva-
lence is upto 10-30% at later stages of the disease. HIV infection leads to bone 
marrow depression causing decreased granulocyte colony-stimulating factor 
levels, thereby causing low granulocyte-macrophage lineage. Thuscausing leu-
kopenia and neutropenia in HIV patients. Bone marrow suppressive drugs or 
opportunistic infections may cause leucopenia. Moreover, HIV infection per se 
results in lymphopenia at later stages of disease, causing low CD4+ lympho-
cytes.  
Various studies from developing nations showed a marked decline in mortality 
in HIV Patients following HAART therapy. An Indian study showed a dramat-
ic decline in mortality from 25 to 5 deaths per 100 person years in HIV patients 
between 1997 and 2003 after starting HAART therapy (19). Factors like older 
age, baseline low CD4 counts,    tuberculosis infection at any point of time and 
ART naive status has significant association with mortality. Higher mortality is 
seen in older age group, mainly above 35 years of age.Studies shows age as a 
poor prognostic factor. It was associated with lower CD4 counts which high-
lights poor prognosis in patients at later stages of the disease. A Brazilian study 
showed 5 times higher chances of death in patients who were symptomatic at 
entry than those who were asymptomatic.(20)  Similar findings were noted in 
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an Jamaican study (21) and in an Indian study on ART naive patients on 
HAART therapy (22).A Sub-Saharan African study reported 8 – 26% mortality 
which is higher than the Taiwan study which showed mortality of  10.2 per 100 
person years. Collaboration of prospective studies from Europe and United 
States showed that ART halved the mortality rate in HIV patients (23). There 
was another Sub-Saharan African study which reported early mortality in pa-
tients accessing HAART programmes and this was because of late initiation of 
HAART and associated opportunistic infections like tuberculosis, cryptococcal 
meningitis, malignancy and wasting syndrome (24). These studies emphasizes  
the need for creating awareness among HIV patients and their health care pro-
viders about early diagnosis of the opportunistic infections and timely initiation 
of HAART before advanced immune suppression occurs  to  reduce the mor-
bidity and mortality. Indian studies showed tuberculosis as the commonest 
among opportunistic infections seen in HIV patients who died   (22)(25)(26). 
This was the basis for, early detection and treatment of HIV as well as TB in 
the National AIDS Control Program of India (NACP). Recently,national guide-
lines in India recommends initiation of anti tubercular treatment (ATT) in HIV-
TB co-infected individuals with lower CD4 count (350 cells/μl). It is recom-
mended to start antiretroviral drugs in these patients after 2 weeks of initiation 
of ATT. A Brazilian study showed dramatic decline in the incidence of tuber-
culosis when HIV diagnosis and treatment were timely done (27).Reports says 
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that early HAART ,that is starting within two months of ATT  is favorable 
compared to late and deferred HAART  in  reducing  mortality  (28) . 
Studies says that at some point of course of HIV illness anemia can be found in 
63%–95% of affected individuals. In the Multistate Adult and Adolescent 
Spectrum of HIV Disease Surveillance Project, Sullivan and col-
leagues,analysed cytopenia in 32,867 persons affected with HIV infection. 
They showed anemia occurrence increases with the clinical severity of the dis-
ease (29). 3% among HIV patients developed anaemia at 1 year follow-up, 
compared to 12% among those who had immunologic AIDS that is CD4 count 
< 200/μL  and 37%  among those with clinical AIDS (32). Among cytopenia, 
anaemia in an HIV-infected individual is significantly correlated with higher 
mortality, and it is independent of the absolute CD4 count and HIV viral load 
(8). But in converse, decreased risk of death has been noted in those who re-
covered from anaemia. Most common reason for anaemia in HIV patients is the 
anaemia of chronic disease. Very low level of CD 4 and CD 11a, expressed by 
CD34+ stem cells, leads them to be resistant to direct viral infection. The mo-
nonuclear macrophage cells develops productive HIV infection and the results 
in the release of cytokines, such as transforming growth factor-beta (TGF-β), 
interleukin 1, tumor necrosis factor-alpha (TNF-α).These cytokines leads on to 
the suppression of  hematopoiesis.Though the levels of serum erythropoietin 
may be high in these patients, the response to anaemia is blunted compared to 
those with uncomplicated iron deficiency anaemia of same severity (30). 
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Drug treatment and the subsequent complications also the common reasons for 
anaemia among HIV patients. Zidovudine is the most common among the ART 
drug to cause anaemia. It inhibits the in vitro erythroid colony formation. It 
does it in a dose dependent manner (31). It is severe anemia, when hemoglobin 
level of less than 7.5–8.0 g/dl or anemia that is requiring transfusion, is noted 
in 24% of those who receive zidovudine 1.5 g /day. Following zidovudine in-
take, macrocytosis develops within weeks. Macrocytosis in these patients also 
acts as a useful marker of drug compliance. But neither vitamin B12 or folic 
acid will help in preventing zidovudine indced bone marrow toxicity. It is 
noted that serum vitamin B12 levels were often low in HIV-infected patients. 
But only a very few patients will have true vitamin B12 deficiency. It is diag-
nosed by elevated levels of homocysteine and also methylmalonic acid (32). 
Human parvovirus B19, DNA virus, which is a single stranded small virus 
cause chronic and severe anemia in HIV patients. This DNA virus affects 
through respiratory tract .This virus reaches erythroid cells by P antigen in the 
blood group. It multiplies ellaborately, ultimately leading onto lysis of the in-
fected cells. Due to the poor humoral immunity in late stages of HIV infection, 
the host response of generating neutralizing immunoglobulin IgM or IgG anti-
bodies become reduced. Hence viremia remains uncontrolled, resulting in ab-
sent red cell production, with an arrest in maturation of erythroid cell lineage. 
Characteristically the giant cells like pronormoblasts were seen in bone marrow 
smears. But these characteristics are not that common, so bone marrow aspira-
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tion is not required for diagnosing parvovirus B19. Alternatively polymerase 
chain reaction assays can be done to diagnose the parvo virus infection. One of 
the study done in University of Washington showed occurrence of this infec-
tion in about 17 percent of HIV patients with anaemia.This was done by dot 
blot hybridization (33) .Treatment includes intravenous immunoglobulin (IV 
IG ) therapy about 400 mg/kg/day for 5 days to give antibodies to clear off the 
infection.This was not successful in many patients (34). There are case reports 
suggesting usage of very active antiretroviral therapy followed by subsequent 
reconstitution of humoral immunity, will lead to the recovery of parvovirus 
B19 infection (35).  
CAUSES OF ANAEMIA: 
DECREASED PRODUCTION  
DRUGS 
 Zidovudine 
 Trimethoprim-sulfamethoxazole 
 Amphotericin B 
 Ganciclovir 
 Dapsone 
 Delavirdine 
Deficiencies 
 Erythropoietin 
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 Iron 
 Folate 
 Vitamin B12 
Infection 
 HIV 
 Parvovirus B19 
 Mycobacterium avium complex (MAC) 
 Mycobacterium tuberculosis 
 Histoplasma capsulatum 
Neoplasia 
 Non-Hodgkin’s lymphoma 
 Multiple myeloma 
 Castleman’s disease 
 Hodgkin’s disease 
 Miscellaneous 
 Anemia of chronic disease 
 Preexisting condition (sickle cell disease, thalassemia) 
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INCREASED LOSS 
HEMOLYSIS 
 Thrombotic thrombocytopenic purpura 
 Glucose-6-phosphate dehydrogenase deficiency 
 (trimethoprim-sulfamethoxazole [TMP-SMX], dapsone, 
 primaquine) 
 Autoimmune hemolytic anemia 
IDIOPATHIC 
DRUGS  
 Ceftriaxone, indinavir, ―Ecstasy‖ 
INFECTION  
 Cytomegalovirus [CMV] 
GASTROINTESTINAL BLEEDING 
 Kaposi’s sarcoma 
 Non-Hodgkin’s lymphoma 
 Infection (CMV, Candida) 
HYPERSPLENISM 
 Infection 
 Lymphoma 
 Hemophagocytosis 
 Cirrhosis (hepatitis B virus [HBV], hepatitis C virus [HCV]) 
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Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB), 
and Histoplasma capsulatum cause anemia in AIDS patients by bone marrow 
infiltration. Patients from Southeast Asia and southern China may also develop 
anemia due to Penicillium marneffei infection .Bone marrow aspiration and bi-
opsy showed the evidence of infection in about 25%–42% of patients tested 
.However, evidence of infection can be made equally faster and accurately us-
ing less-invasive modalities like blood culture, serology, or nucleic acid hybri-
dization. Especially true in case of mycobacterial infection. Bone marrow re-
sults in unique diagnosis, only in about 10% of the performed procedures, and 
is more likely to be helpful in patients with low CD4 counts or a hematocrit 
less than 25%. Surprisingly, autoimmune hemolytic anemia (AIHA) is not that 
common among HIV infected patients. Though the prevalence of a positive di-
rect anti globulin test (DAT) ranges from 18% to 43% in this population, only 
few case reports about HIV-associated AIHA are there. Generally DAT-
positive patients have lower hemoglobin levels than DAT-negative patients. 
This is because of the prevalence of DAT-positivity. Among the few cases of 
symptomatic autoimmune hemolytic anemia reported in HIV infected patients, 
both warm and cold antibodies have been noted, simultaneously. Reticulocyto-
penia is relatively frequent among HIV infected individuals hence its presence 
cannot be used to rule out hemolysis. But they show decreased haptoglobin 
level and elevated lactate dehydrogenase level, and bone marrow will be show-
ing normocellular with erythroid hyperplasia. Treatments with corticosteroids, 
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intravenous immunoglobulin, withdrawal of any offending drugs, and splenect-
omy has shown success (36). Aggressive transfusion therapy should be handled 
with extra caution in HIV-associated AIHA, because of fatal pulmonary embo-
lization due to increased hemolysis and disseminated intravascular coagulation 
which has been documented (37). Indinavir, ceftriaxone, and ―Ecstasy‖ have 
been reported to cause hemolytic anemia in AIDS patients. Rarely, cytomega-
lovirus (CMV) infection also can cause hemolysis. Easy fatiguability is the 
main symptom of anemia, is also the most common symptom of HIV infection 
and is responsible for impaired physical function and poor quality of life. Many 
of the randomized, double-blind and placebo-controlled trials using a variety of 
regimens have noted that the use of recombinant human erythropoietin in HIV-
associated anemia frequently augments the hemoglobin levels, fewer transfu-
sions and a better quality of life. 
 One of the observational study done at Johns Hopkins hospital under HIV 
Clinic, showed among treatment of anaemic patients with erythropoietin re-
sulted in a significantly decreased mortality. But in contrast, many studies sug-
gested that transfusion therapy, early in the course of HIV infection, has been 
associated with increased mortality. Reason for this includes the transfusion-
associated infection with agents such as CMV, hepatitis B and C, human T-cell 
lymphotropic virus (HTLV I/II) or parvovirus B19,transient activation of HIV 
expression; and transfusion-associated immune suppression which is mediated 
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by inflammatory cytokines that cause decreased lymphocyte, NK cell, and   
monocyte function. 
Randomized trials done to compare the use of leuko reduced against unmodi-
fied red blood cells in patients with advanced stage of infection showed no evi-
dence of cytokine activation post transfusion. Moreover, leuko reduction does 
not give any clinical benefit and have even lessen the survival. More number of 
transfusions can lead onto iron overload. This may aggravate progression of 
HIV and increases the susceptibility to infection by reducing macrophage func-
tion .Infections like oesophageal Candidiasis, Pneumocystis jiroveci and myco-
bacterium TB can occur. 
HIV WITH  THROMBOCYTOPENIA 
Human immunodeficiency virus which is a retrovirus affecting immunity, im-
pairing their immune function, thus leads on to the occurrence of opportunistic 
infections and malignancies. Hallmark of HIV infection is decreasing activity 
and number of CD4+ T lymphocytes and it also impedes other cell lineages and 
tissues. Cytopenias have been noted even without HAART or opportunistic in-
fections and malignancies, proves that HIV infection is directly associated in 
causing these hematological derangements. Interestingly, thrombocytopenia is 
noted as the first clinical manifestation in otherwise asymptomatic HIV in-
fected individuals. Neutropenia and anaemia are mostly noted in the later stag-
es of HIV disease .Thrombocytopenia is identified if platelet counts are below 
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125000/mm3, and commonly occurs in HIV infected individuals. Possible me-
chanisms considered for thrombocytopenia are increased destruction of plate-
lets, by immune complexes in circulation which are nonspecific gets deposited 
on the platelets or by the existence of specific anti-platelet antibodies, as well 
as direct action on megakaryocytes by HIV per se causing ineffective platelet 
production. Thrombocytopenia incidence among HIV patients is about 40% 
and in 10% of HIV patients, it may be the first sign of AIDS. Mature Megaka-
ryoctes (MKs) gets affected by the HIV through CD4 receptor binding, and 
HIV genomes were detected in MKs that were purified from the bone marrow. 
MKs are affected by both X4- and R5-tropic HIV-1strains thus representing 
thrombocytopenia occuring in initial period of HIV infection. In earlier stages 
of the disease, in addition to the direct effects on MK cell lines, HIV also leads 
on to chronic thrombocytopenia by autoimmune mechanisms. Auto -immune 
mechanisms by molecular mimicry causing cross-reaction of anti-HIV antibo-
dies against platelet membrane glycoproteins. Thrombocytopenia is related to 
increased morbidity and mortality, by accelerating the deterioration of CD4 
counts and leading on to progression to AIDS.  
It was in the year 1982, the association between HIV and thrombocytopenia 
has been reported for the first time (38).Now immune thrombocytopenic purpu-
ra (ITP) remains the most common cause of low platelet count in these patients 
. It is estimated about 30 percent occurrence (39) .ITP occurs in early stage of 
HIV infection because of platelet associated antibodies and occurs even before 
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other manifestations of the infection.HIV-associated ITP is commonly seen 
among men than women.  
CAUSES OFTHROMBOCYTOPENIA 
DECREASED PRODUCTION 
Drugs 
 Trimethoprim-sulfamethoxazole 
 Pentamidine 
 Pyrimethamine 
 Ganciclovir 
 Fluconazole 
 Alpha-interferon 
 Rifabutin 
 Clarithromycin 
 Didanosine 
 Amphotericin B 
 Indinavir 
 Ritonavir 
 Delavirdine 
 Nelfinavir 
 Deficiencies 
 Folate 
 Vitamin B12 
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Infection 
 HIV 
 Parvovirus B19 
 Mycobacterium avium complex (MAC) 
 Mycobacterium tuberculosis 
 Histoplasma capsulatum 
 Bartonella henselae (bacillary angiomatosis) 
Neoplasia 
 Non-Hodgkin’s lymphoma 
Miscellaneous 
 Preexisting condition 
INCREASED LOSS 
 Immune thrombocytopenic purpura 
 Thrombotic thrombocytopenic purpura 
 Hypersplenism 
 Infection 
 Hemophagocytosis 
 Cirrhosis 
Drugs 
 Saquinavir 
 Interferon 
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Dominguez and coworkers noted platelet kinetics in 41 HIV patients with 
thrombocytopenia and found that the platelet survival was decreased in those 
with CD4 counts >200 Cells / µl than in those with counts <200, which shows 
that platelet destruction is more in patients with higher CD4 levels, and de-
creased platelet production is more among those with lower CD4 levels (40). 
Similar studies done by Cole et al showed that in HIV infected individuals 
there is ineffective delivery of viable platelets to the peripheral circulation, de-
spite a 6-fold rise in thrombopoietin levels and a 3-fold expansion of megaka-
ryocyte mass compared to the normal control groups (41). This gives the possi-
bility of HIV-induced apoptosis of megakaryocytes and it correlates with the 
results of kinetic experiments, which showed increased platelet turnover but no 
change in platelet survival after zidovudine therapy. This indicates that the 
platelet production improves during treatment. Features of megakaryocytic in-
fection by HIV virus includes denuded nuclei and ballooning of the peripheral 
zone of megakaryocytic cytoplasm which were observed by electron microsco-
py. Internalization of HIV particles were noted in co culture studies. The      
immuno histochemical techniques showed the presence of the HIV p24 antigen 
and HIV RNA expression noted using in situ hybridization. 
Infections, malignancies or drugs can also lead onto impaired platelet produc-
tion and thrombocytopenia, by bone marrow infiltration. About 8% of HIV pa-
tients have thrombocytopenia leading onto hemorrhagic event (42).Treatment 
is required only when platelet count is < 30,000/μl or if  they are symptomatic. 
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Patients with coagulopathies and hemophilia must be requiring therapy when 
the platelet counts are < 50,000/μl , inview of very high bleeding risk..About 
18% of patients with HIV-associated thrombocytopenia goes for spontaneous 
remission.   
Specific treatment modalities for HIV-associated ITP includes corticostero-
ids,IVIG, intravenous anti-D therapy, splenectomy, danazol, interferon, and 
vincristine. Prednisone 1 mg/kg /day, increases the platelet count in many of 
the HIV patients but long-term use will result in Cushing’s syndrome. It also 
accelerates the course of Kaposi’s sarcoma and increases the risk of fungal in-
fection .IVIG infusion induces quicker but unsustained remissions in about 
71%–100% of HIV patients and it is also costlier (43).  
Intravenous anti-D therapy increases the platelet count > 50,000/μl only in 34% 
of patients treated with it but it is less expensive. The response to anti-D is 
longer than that seen with IVIG therapy but the extent of hemolysis is unpre-
dictable with D+ (Rh+). In patients with baseline hemoglobin levels > 12 g/dl 
are likely to have an elevation of their platelet counts than those with anemia. 
Splenectomy is also found to be successful and, despite early concerns, does 
not obviously increase the risk of progression of HIV infection to symptomatic 
AIDS. A cohort study of 45 individuals and about 17 had splenectomy. In 28 
individuals who did not have splenectomy, demonstrated a significant reduc-
tion in the risk of developing full-blown AIDS and showed reduced mortality 
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in splenectomized patients (44). This may be because of temporary reduction in 
plasma viremia and an increase in absolute CD4 and CD8 levels. 
Thrombotic microangiopathy (TMA) is also a noted complication of HIV dis-
ease. It is seen in 1.4% of affected patients prior to the introduction of anti re-
troviral therapy (45).Both thrombotic thrombocytopenic purpura (TTP) and 
hemolytic uremic syndrome (HUS) were documented. When compared to TTP, 
HUS is more noted at advanced stages of HIV disease and found to be treat-
ment refractory and results in death. 
NEUTROPENIA 
In HIV patients lower values of absolute neutrophil counts are because of gra-
nulopoiesis inhibition by the HIV virus itself or by bone marrow infiltration by 
infections .It can occur due to malignancies, adverse drug reactions, autoim-
munity, and also due to hypersplenism. 
CAUSES OF NEUTROPENIA: 
Decreased Production 
 Drugs 
 Ganciclovir 
 Zidovudine 
 Trimethoprim-sulfamethoxazole 
 Pentamidine 
 Rifabutin 
 Antineoplastic chemotherapy 
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 Dapsone 
 Amphotericin B 
 Ritonavir 
 Delavirdine 
 Nelfinavir 
 Deficiencies 
 Folate 
 Vitamin B12 
 Infection 
 Human immunodeficiency virus (HIV) 
 Mycobacterium avium complex (MAC) 
 Mycobacterium tuberculosis 
 Histoplasma capsulatum 
 Neoplasia 
 Non-Hodgkin’s lymphoma 
 Multiple myeloma 
Increased Loss 
 Autoimmune neutropenia  
 Hypersplenism 
 Infection 
 Hemophagocytosis 
 Cirrhosis 
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Neutropenia in HIV patients is treated by initiation of antibiotic therapy for the 
evidence of infection; antiretroviral therapy for those who remain untreated for 
HIV infection; withdrawing of potential offending drugs; and myelopoiesis 
stimulation using either   granulocyte colony stimulating factor (G-CSF) or 
granulocyte macrophage colony stimulating factor (GM-CSF). 
THROMBOSIS 
Thrombosis in HIV-infected patients has been reported up to 2%. Venous 
thromboembolic complications are associated with factors like age more than 
45 years, advanced stage of HIV infection, the presence of AIDS-defining op-
portunistic infections,treatment with indinavir or megestrol acetate (46). Im-
mobilisation due to illness is commonly behind the association between oppor-
tunistic infections and thrombosis (47). But in case of CMV infection, it pro-
motes adhesion of platelets and neutrophils to the endothelium which will in-
duce production of anti phospholipid antibodies.These enhance synthesis and 
increases the secretion and survival of factor VIII and von Willebrand factor 
(48). Reason for indinavir induced thrombosis is unclear, but megestrol, like 
many other progestational agents, leads to acquired resistance to activated pro-
tein C. 
Moreover individuals with HIV infection will be at increased risk for thrombo-
sis because of  the various reasons like  decreased levels of anti thrombin, pro-
tein C and S, or heparin cofactor II; coexistence of malignancy , autoimmune 
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or inflammatory disorders; the presence of anti cardiolipin antibodies or vascu-
lar damage due to injection drug use, intravenous catheter placement or CMV 
infection.  
Anti thrombin deficiency occurs in association with HIV nephropathy as a re-
sult of loss of anti thrombin in the urine. The nephrotic syndrome which is seen 
in HIV nephropathy may be resulting in compensatory hepatic synthesis of fac-
tors V, VIII, and X induced by hypoalbuminemia and thereby increased platelet 
adhesion and aggregation (49). Acquired protein S deficiency is seen in upto 
75% of HIV-infected children and adults. This is especially seen in patients 
with CD4 counts < 200/μl or AIDS and results in thrombotic complications in 
upto 12% (50). Free protein S antigen levels in HIV infected patients can be 
appearing artificially lower when assayed by PEG precipitation method, so that 
the prevalence of protein S deficiency in HIV patients may actually be lower 
than previously thought of about 10% (51). Lupus anticoagulant is noted in 
about 0- 70% of HIV patients, depending on the sensitivity of the assay used 
and the patients characteristics. Anti cardiolipin antibodies are found in 46-
90% of the HIV patients. Neither in HIV is strongly associated with high risk 
of venous thromboembolic manifestations, but events such as multiple transient 
ischemic attacks ,stroke, skin necrosis, avascular necrosis of bone and brachial 
artery thrombosis have rarely been described in patients with anti cardiolipin 
antibodies (52). 
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Hemophagocytic Syndrome in HIV: 
Hemophagocytic syndrome in HIV infected individuals is a rare associa-
tion.Pancytopenia ,high grade fever,enlargement of the spleen and lymphade-
nopathy are the features.This syndrome has characteristic bone marrow histi-
ocytosis and blood cell precursor phagocytosis.HIV infection per se can cause 
this syndrome or this can occur because of the association cytomegalovirus, 
HSV,histoplasmosis,TB,human herpesvirus 8, and parvovirus B19 infec-
tions.This hemophagocytosis lead onto worsening of malignancies like non-
Hodgkin’s lymphoma and Kaposi’s sarcoma (53). 
VIRAL MARKERS 
Surrogate markers of treatment responses in HIV patients are HIV viral level 
and absolute CD 4 T lymphocyte level. HIV RNA load is an important marker 
for assessing the treatment response .Viral load level prior to HAART and level 
of decrease after treating with drugs provides details regarding prognosis and 
about the possibility of progression of illness (54).Main target of ART is to at-
tain a sustained very low viral level. Hence HIV viral level is used to look for 
the efficiency of ART following commencement. CD4 counts are measured 
during initiation of treatment with ART. It gives the estimate of overall im-
mune status of HIV patient. Absolute CD4 count is very critical to establish the 
thresholds for the starting and discontinuing prophylaxis for opportunistic in-
fections and in deciding the initiation of ART. 
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With the availability of more potent anti retroviral drugs management of HIV 
infection has changed substantially. In USA, ART is provided to all HIV in-
fected individuals regardless of their immune status as assessed by HIV viral 
level and absolute CD4 cell count. 
HIV -RNA VIRAL LEVEL:  
Human immunodeficiency virus (HIV) infection is persistent and progressive 
in majority of untreated individuals .There is a strong proof that HIV specific 
cellular immune responses are the key in determining the viral replication tem-
po and their clinical course of the disease. The proof for this protective immune 
mechanism comes from the rhesus macaque model of SIV (simian immunode-
ficiency virus) infection. It  shows (i) CD8
+
T-cell function interference with  
monoclonal antibody mediated destruction increases  replication of HIV and 
(ii) CD8
+
 cytotoxic T lymphocytes (CTL) has the capacity to exert prime pres-
sure on the HIV  genome, and this is evident by faster appearing specific es-
cape mutations in epitope-encoding sequences. Recently studies shows vac-
cines capable of exhibiting viral specific CD8
+
 T-cell responses which controls 
HIV  replication and prevention of disease occurrence (55).  
The recent Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected 
Adults and Adolescents given in the website  
 http://aidsinfo.nih.gov/guidelinesare as follows 
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HIV-1 VIRAL LOAD ASSESSMENT: 
Human immunodeficiency virus RNA is a good marker of early and sustained 
treatment response (AI) .Viral load has to be measured among all patients dur-
ing their first visit (AIII), at the commencement of treatment (AIII), and during 
follow up. Those who are not opting treatment, viral load testing is an optional 
(CIII).HIV Viral load prior to treatment is necessary to decide which regimen 
of ART to be started. This choice of regimen is because present ART drugs 
show poor responses if there is a very high level of HIV viral load. HIV-1 RNA 
assays which are available currently does not detect HIV 2 viral load.  
Many systematic analysis of data through clinical trials showed marked de-
crease in viral load following HAART (54,56). Therefore viral load testing is 
an important marker correlating to the treatment response in HIV patients. Ob-
servers noticed that 3 fold change in viral load that is approximately 
log10 copies/micro liter is statistically significant. If the viral load is consistent-
ly below the detection level <20 to 75 copies/ micro litre it is called Optimal 
viral suppression. However in few successfully treated HIV patients the viral 
levels remains temporarily lower about HIV RNA level < 400 copies/ micro 
litre  and that is  not predictive of so called virological failure 
(57). Furthermore, review on data regarding the association between sustained 
low levels of about HIV viral load < 200 copies /micro litre ,the virologic fail-
ure is bit controversial. There is one study which showed more chance of fur-
ther failure at this viral load level but this association was not proved in other 
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studies. AIDS Clinical Trials Group (ACTG)which defines virological failure if 
viral load >200 copies/micro litre. This is the level that eliminates apparent vi-
remia caused by viral load blips and variabilities in the assays. 
Those who are adherent to ART achieve their viral load suppression in 8-24 
weeks of treatment and they do not tend to harbor resistant strains .Only very 
rarely in few HIV patients it takes longer time to achieve virological suppres-
sion.   
RECOMMENDATIONS FOR VIRAL LEVEL ASSESSMENT:   
Following ART commencement / treatment adjustment due to virological fail-
ure, HIV viral load has to be measured within 2 to 4 weeks after treatment init-
iation or modification but not later than 8 weeks (AIII). This is needed for 
knowing adequacy of virological response to treatment and regularity in drug 
intake. HIV viral level has to be repeated in 4 - 8 weeks interval till the viral 
load level falls less than the detection limit (BIII). 
Patients with previously attained virological suppression or in those with treat-
ment change due to side effects or simplifying the treatment, HIV RNA level 
has to be done in 4 - 8 weeks following change of treatment regimen (AIII). 
This is to confirm that the new regimen is effectively bringing virological sup-
pression or not.    
In patients who are on a stable and effective ART regimen, HIV viral load has 
to be done in every three to four months (AIII) or else when needed to decide 
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maintained viral suppressive state. If patient is adherent to drugs and viral load 
is suppressed for nearly 2 years than clinicians can extend to every 6 months 
monitoring of viral load.   
Patients who has less optimal response ,HIV viral level has to be monitored de-
pending on the clinical circumstances, like adherence and if there is options for 
further treatment available. 
CD4 COUNT MONITORING:  
In HIV patients, absolute CD4 cell count acts as the main indicator of immuno-
logical status and acts as a marker of ensuing progression of illness and mortal-
ity .This is based on  the clinical controlled trials and studies across the 
world.These counts are very much variable. Statistically significant difference 
among 2 tests is about a thirty percentage change in the absolute CD4 count, or 
a 3 percentage point increase or decrease in the CD4 percentage. Measuring 
lymphocyte subsets like CD8, CD19 other than CD4 has not found to be clini-
cally useful. They are costlier and hence not suggested (BIII).   
CD4 CELL COUNT FOR INITIAL JUDGEMENT:  
Absolute CD4 cell count must be monitored in every patient at the reach of 
medical service (AI). CD4 counts are the important factor in deciding the need 
of initiation of opportunistic infection prophylaxis and the urgency in initiating 
ART (AI). Most of the opportunistic infections occur in patients whose CD4 
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counts were less than 200 cells/ cubic mm.Sometimes opportunistic infections 
were noted among patients with higher absolute CD4 cell level (58). 
TREATMENT RESPONSE ASSESSMENT WITH ABSOLUTE CD4 
CELL COUNT :    
The immunologic response in HIV patients who were treated with ART is as-
sessed with CD 4 cell counts .CD4 count is also used to decide whether proph-
ylaxis for opportunistic infection can be discontinued or not. Mostly in patients 
on ART, CD4 cell count has to be raised upto 50 to 150 cells/ cubic mm during 
the first year of treatment.Then only it is said as adequate response.Mostly they 
show an increased response in the first three months of ART. Thereafter they 
have an average increase of upto 50 - 100 cells /mm
3
 / year till reaching steady 
state in those who start treatment at a lower lymphocytes or those in old 
age.They usually have small increase in the cell counts even though they show 
virological suppressive state.  
 ABSOLUTE CD4 CELL COUNTS MONITORING:   
Now treatment is recommended for all HIV positive patients. If patients not on 
treatment, CD4 counts has to be done every 3 to 6 months for assessing urgent 
need of ART commencement and starting opportunistic infection prophylax-
is at right time (AIII). 
Level of immune reconstitution can be assessed by measuring a repeat CD4 
count after 3 months of ART initiation (AIII). This measurement is critical in 
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patients in whom ART is initiated at more advanced disease and in those re-
quiring opportunistic infection prophylaxis or treatment. The time and extend 
for CD4 cells raise is needed to decide on continuation / stoppage of opportu-
nistic infection prophylactic treatment. In situation like this and in the initial 
two years of treatment, CD4 cell count can be done in 3 to 6 months inter-
val time (BII). 
It is rarely indicated to change the drug regimen if there is poor CD4 response 
in an individual with good virological response. In those who have consistent 
suppression of viral loads and already attained ART-mediated immune recons-
titution, level of CD4 count gives only little information. So frequent monitor-
ing is unnecessary as it is not going to change the clinical management. A re-
trospective study showed that CD4 count of less than 200 cells/mm
3
 are rare 
among HIV patients who has viral suppression and they usually had CD4 
counts more than 300 cells/mm
3
.The ARTEMIS trial has showed that CD4 test-
ing had no benefit in patients who had viral load suppression and in those who 
had CD4 counts more than 200 cells/mm
3
 after 48 weeks treatment with ART.  
Studies found that in patients who have CD4 counts between 100 -200 
cells/mm
3
,the risk of Pneumocystis jirovecii pneumonia is very low who is on 
suppressive ART. Rarely in few patients with virological suppression,CD4 
counts were very low and is associated with worst outcomes like ischemic heart 
disease, tumours and high mortality. In United States it is found that cost anal-
ysis of monitoring CD4 count every 12 months instead of 6 months could save 
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10 million dollars annually.Those who are on suppressive regimen with their 
CD4 count consistently found to be between 300 -500 cells/mm
3
 for minimum 
of 2 years, then the Panel recommends monitoring of CD4 count can be done 
on an annual basis (BII). It is optional to monitor CD4 count in patients who 
has virological suppression and whose CD4 counts are consistently above 500 
cells/mm
3
 for minimum of 2 years (CIII). CD4 cell count must be done fre-
quently, if clinically necessitated, if there are changes in the status clinically 
that would reduce CD4 cell count then CD4 count has to be monitored fre-
quently and thus prompt opportunistic infection prophylaxis. Frequent monitor-
ing is needed when changes like occurrence of new HIV related symptoms or 
commencement of drugs which cause reduction in CD4 cell count like corticos-
teroids or chemotherapeutic agents or interferon alpha(AIII). In patients with 
virological failure while adhering to treatment, CD4 cell count has to be done 
in every 3 to 6 months  interval (AIII).   
FACTORS THAT AFFECT ABSOLUTE CD4 COUNT: 
On the basis of total leucocytes and total lymphocyte % and percentage of CD4 
lymphocytes, value of CD4 count can be calculated. This absolute count may 
vary in individuals with the presence of acute infections and use of ART of 
which some are bone marrow-suppressive medications. In patients who have 
undergone splenectomy or co-infected with human T-lymphotropic virus type I 
(HTLV-1) there may be elevated CD4 counts, which would be misleading. Al-
pha-interferon therapy  affects only the CD4 counts and not the percentage of 
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CD 4. CD 4 percentage remains stable in all these conditions and it may be the 
more appropriate marker to assess immune status of HIV patients.    
DRUG-RESISTANCE TESTING        
Testing for the drug resistance in HIV is suggested in all the patients during 
their first attendance to treatment centre. It has to be done for all patients for 
whom initiating antiretroviral therapy (ART) sooner or later (AII). Planned for 
ART later, then drug resistance test has to be done again at the initiation of 
ART regimen (CIII). In ART naive patients, genotypic testing is more pre-
ferred hence it is recommended (AIII). Standard method of genotypic testing of 
drug resistance includes testing for the RT (reverse transcriptase) and PR (pro-
tease) gene mutations. If RT and PR gene mutations are transmitted then INSTI 
(integrase strand transfer inhibitor) gene mutation has to be analysed (CIII). 
Drug-resistance testing is performed to decide on changing treatment regimen 
in those HIV  patients with virological failure and in those with HIV viral load 
above1,000 copies/millilitre (AI). Even the drug resistance tests are unsuccess-
ful among patients with HIV viral level above 500 but below 1000 cop-
ies/millilitre, testing is still to be considered (BII). 
If there is suboptimal  reduction in viral load ,then drug testing has to be consi-
dered (AII). Patients who fail from INSTI-based regimens, then INSTI resis-
tance testing has to be done to know about adding drugs from this group (AII). 
If there is viral failure drug resistance tests has to be done when patient is on 
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the ARV medications otherwise within four weeks from discontinuing drugs 
(AII). When four weeks has lapsed from stoppage of drugs, still resistance test-
ing gives useful information regarding the choice of treatment, but the pre-
viously selected gene mutations can be missed (CIII). While on first or second 
ART regimens genotypical tests are the resistance testing of choice, which 
guides treatment incase of virological failure (AII). The phenotypic drug test-
ing is added to the genotypic testing generally for suspected or known mutation 
patterns mainly protease inhibitors (BIII).  
For all pregnant women prior to initiation of ART, Genotypic drug resistance 
testing is recommended (AIII) and also for those who are already on ART with 
detectable viral load and entering pregnancy (AI).  
 CO-RECEPTOR TROPISM ASSAYS:  
Panel recommendations are: Whenever considering treatment with CCR5 co-
receptor antagonist co-receptor tropism assay has to be performed (AI). If not 
achieving viral load suppression with CCR-5 antagonist,then this tropism test-
ing assay is recommended (BIII). For determining HIV-1 co-receptor usage a 
phenotypic tropism is the recommended choice of assay (AI).   
Genotypical tropism assay can be used as an other test to analyse HIV 1 co-
receptor usage  (BII).   
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SCREENING FOR HLA B-5701 : 
Before treating patients with abacavir (ABC) containing ART regimen, the 
Panel recommends to screen for HLA-B*5701 thereby the hypersensitivity 
reaction risk can be avoided (HSR) (AI). Those who are show HLA B-5701 
must not be treated using ABC (AI). If HLA-B*5701 found positive then it has 
to be mentioned as ABC allergy in the medical records of the patient (AII). If 
HLA B -5701 screening is not possible, then ABC has to be initiated with 
proper counselling explaining the risk and has to be monitored for any signs of 
HSR (CIII).   
Initiating Antiretroviral Therapy in Treatment-Naive Patients: 
 All HIV infected patients has to be treated with Anti retroviral therapy (ART) 
to decrease the risk of progression of the disease. Strength and evidence for this 
recommendation differs according to the pretreatment CD4 count level:  
 CD4 count level less than 350 cells / cubic mm
 
(AI) 
 CD4 count level 350 - 500 cells/ cubic mm
 
(AII) 
 CD4 count level more than 500 cells / cubic mm (BIII).  
ART is advised for HIV patients to cut down the HIV transmission. Strength 
and evidence of this recommendation is according to the risk of transmission 
like in perinatal transmission (AI), in hetero-sexual transmission (AI) and other 
risk groups mentioned (AIII).  
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Before commencing treatment patient has to be motivated for treatment adhe-
rence and commits to continue therapy and he must know the advantages of 
treatment and need for treatment adherence (AIII). Patient has the right to post-
pone therapy, and providers can opt to delay therapy on individual case by case 
basis, depending on clinical basis and psychosocial factors.  
COMBINATION ART REGIMENS FOR INITIATING THERAPY FOR 
TREATMENT NAIVE PATIENT: 
For a treatment-naive patient treatment has to be started with two NRTI (nuc-
leoside reverse transcriptase inhibitors) and the third drug should be an active 
drug from following groups - an integrase - strand transfer inhibitor or NNRTI 
(non- nucleoside reverse transcriptase inhibitor) or PI (protease -inhibitor) .This 
regimen has to be given along with an enhancer like either cobicistat or else 
ritonavir.  
 DRUGS FOR TREATMENT NAIVE INDIVIDUALS:  
Integrase Strand Transfer Inhibitor-Based Regimens:  
 • Lamivudine /abacavir or dolutegravir—this has to be used in 
those who are negative for HLA B -5701 (AI) 
 • Tenofovir/dolutegravir /emtricitabine (AI) 
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 • Tenofovir/elvitegravir/cobicistat/emtricitabine— this has to be 
used only in those who have CrCl >70 mL/min prior to antiretro-
viral therapy (AI) 
 • Raltegravir / emtricitabine /tenofovir (AI) 
Protease Inhibitor (PI)-Based Regimen:  
               • Tenofovir/emtricitabine plus darunavir/ritonavir (AI)  
Emtricitabine and lamivudine can be exchanged. 
Regimen to initiate the therapy should be guided by considering the following 
factors like virological efficacy, toxicity of the drugs,frequency of dosing, 
drug-drug interactions, results of resistance testing, comorbid illness, and the 
cost of the drugs.  
MANAGEMENT OF THE TREATMENT-EXPERIENCED PATIENT: 
Expert advice should be sought in case of virological failure. It is a complex 
process to assess and manage a patient experiencing  antiretroviral therapy fail-
ure. In case of virologic failure adherence to drugs, interactions to drugs, treat-
ment history, drug tolerability, HIV viral load and absolute CD4 cell counts 
and drug-resistance tests has to be looked for. If failure to antiretroviral (ARV) 
regimen is doubted drug resistance testing has to be performed (AI) in 4 weeks 
from discontinuation of drugs (AII). If 4 weeks after discontinuation also 
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though it may not be detecting previously selected resistance mutations, resis-
tance testing can still provide useful information to guide the therapy (CIII). 
In treatment experienced patients who has virologic failure with drug resis-
tance,the goal of treatment is to attain virological suppression ,that is to bring-
down HIV viral load below detectable limit  (AI).  
2 or 3 completely active drugs has to be given in newer combination (AI).Drug 
which is expected to have no drug resistance and with newer mechanism of ac-
tion is considered to be entirely active pill.  
Because of development of drug resistance, single drug should not be added to 
a failing regimen (BII).  
In treatment experienced patients attaining good suppression is difficult (AI) 
hence regimens are designed to reduce toxicity and delay the clinical progres-
sion rate.  
POORER CD4 COUNT RECOVERY AND SUSTAINED INFLAMMA-
TION EVEN AFTER VIROLOGICAL SUPPRESSION 
In HIV infected patients, complications from many AIDS and not pertaining to 
AIDS conditions are augmented even in those who are on antiretroviral treat-
ment mediated  virological suppression .These are predicted by sustained lower 
CD4 cell counts and consistent immune activation. Anti retroviral drugs should 
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not be added to suppressive regimen for augmenting the response since it does 
not improve CD4 cells hence it is not recommended (AI).  
In those who attained virological suppression, switching over of ARV drug 
classes does not always improve CD4 cell counts or decrease immune activa-
tion and it is not  recommended (BIII).  
Presently interleukin-2 is not suggested to raise the CD 4 counts [AI] .None of 
these agents are proven to bringdown the severity while on ART mediated viro-
logical suppression.  
Testing the immune activation markers and inflammatory markers are not sug-
gested by the panel.Mostly markers predicting the severity shows fluctuating 
results among these patients (AII).  
Since no methods to raise CD4 counts, only the modifiable risk factors has to 
be addressed like avoiding smoking, following healthy diet pattern and control-
ling hypertension and hypercholestrolemia (AII).  
  
THERAPEUTIC DRUG MONITORING (TDM) FOR ANTIRETRO-
VIRAL AGENTS  
There is no recommendation about therapeutic drug monitoring of antiretrovir-
al drugs for regular use in HIV patients management purpose (BII). 
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ANTIRETROVIRAL USE IN SPECIAL PATIENT POPULATIONS 
ACUTE AND RECENT (EARLY) HIV INFECTION: 
For all with HIV type 1 infection and with earlyHIV-1 infection antiretroviral 
therapy (ART) is recommended (BII), still strong information regarding its vi-
rological, immunological and clinical success are not available. Pregnant wom-
en in early stage of infection, the treatment should be commenced as early as 
possible to cut down perinatal transmission of HIV (AI). If treatment is 
started,the goal should be to bring down viral load to undetermined level 
(AIII).  
If antiretroviral therapy is started in patients with early HIV-1 infection , check 
for the HIV-1 viral load, absolute CD4  cell counts as done in chronic HIV-1 
infection (AII).  
Before initiation of ART,the genotypical resistance testing of drugs should be 
done to choose the ART  regimen (AII). Genotypic drug resistance has to be 
done even if the treatment is deferred for time being,since it would be useful in 
deciding the regimen for attaining optimal virological response if treatment is 
once commenced (AII).  
If no drug resistance is found,then antiretroviral treatment has to be started . 
One of the combined regimen that is recommended for chronic HIV type 1 in-
fection has to be used (AIII).  
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Antiretroviral treatment must be started before the resistance test are results are 
available for the drugs, since resistance to protease inhibitors developed in 
slower rate and also the resistance to protease inhibitors that are clinically sig-
nificant is not that common. Protease inhibitors and two nucleoside reverse 
transcriptase inhibitors has to be used (AIII).  
ART should be started in individuals who are committed to the treatment .They 
should be educated about the risks of treatment discontinuation and they must 
understand the importance of taking drugs regularly (AIII). These patients has 
the right to postpone the treatment until it is convenient for them . 
WOMEN WITH HIV INFECTION: 
 Goal for starting of antiretroviral therapy in HIV-infected women are similar 
to other HIV infected adults and adolescent groups (AI). To prevent unintended 
pregnancy , those women who are on antiretroviral (ARV) drugs should use an 
additional or alternative contraceptive method, if their oral contraceptives  have 
significant pharmacokinetic interactions with antiretroviral drugs.(AIII).  
In pregnant women, HIV transmission perinatally should be prevented and it is 
an additional goal of therapy .The goal is effective virological suppression so 
that to bring down the risk of HIV transmission among the fetus and also in the 
newborn (AI). While selecting an antiretroviral regimen to use in pregnancy, 
physician must analyse the efficacy, other pharmacokinetic details and safety 
of each antiretroviral agent (AIII).  
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Before the initiation of efavirenz (EFV) childbearing aged women must check 
pregnancy tests and should receive information regarding the danger to the fe-
tus and effective contraception methods to be taught while she on efavirenz 
based regimens (AIII). In case if they are planning pregnancy then efavirenz 
contained regimens should be totally avoided. 
In  efavirenz based regimen the risk of neural tube defects (NTD) are restricted 
to first 5 to 6 weeks of pregnancy but pregnancy is recognized rarely before 4 
to 6 weeks of    pregnancy.So that efavirenz can be continued in pregnant 
women who is receiving an efavirenz based regimen and presenting for ante-
natal care in the first trimester, provided the regimen resulting in virological 
suppression (CIII).  
Mainly when designing a particular regimen for a pregnant woman, physician 
should always consult the most current Health and Human Services (HHS) Pe-
rinatal Guidelines (AIII).  
SUMMARY OF HIV-2 INFECTION: 
Generally HIV 2 infection disease course is marked by a long asymptomatic 
period ,compared to HIV type 1 infection .There will be usually lower HIV-2 
RNA levels in the plasma and lower mortality rate but then progression to 
AIDS also occurs in HIV 2 infection .Antiretroviral treatment must be com-
menced prior to the occurrence of       progression of the disease. 
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HIV-2 is usually resistant to the drugs like non nucleoside reverse transcriptase 
inhibitors and also resistant to enfuvirtide. Hence non nucleoside reverse tran-
scriptase inhibitors and enfuvirtide should not be used in ART regimen for a 
HIV type 2 infected individual.  
Definitive information about the outcome of  antiretroviral therapy in a treat-
ment naive patient with HIV-2 infection alone or HIV-1 and HIV-2 infection 
are pending.In these patients 2 nucleoside reverse transcriptase inhibitors and 
one HIV-2 infection active boosted protease inhibitor or one integrase strand 
transfer inhibitors must be commenced. But there are no validated tests to as-
sess HIV-2 RNA load or absolute CD4 counts as done in case of  HIV type 1 
infection. But if there are no improvement in either clinical/virological 
/immunological status then an expert opinion is required. 
HIV IN OLDER PATIENT: 
Since there is increased risk of many complications that are not AIDS related 
ones and the reduced immunity to ART in older HIV infected pa-
tients,treatment with ART is recommended in all patients  who are aged above 
50 years with HIV infection, irrespective of their absolute CD4 count (BIII).  
Older HIV infected individuals are more prone for ART-associated adverse 
events than younger HIV infected individuals.There is high chance of drug in-
teractions among antiretroviral agents and other drugss which are routinely 
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used in elderly HIV infected patients. Hence they have to be monitored period-
ically, mostly while commencing ART or changing drugs.  
HIV AND HEPATITIS B VIRUS CO INFECTION  
Before starting ART,all HIV infected patients who are positive for hepatitis B 
surface antigen (HBsAg) should undergo hepatitis B virus DNA measurement 
by quantitative analysis .This finds out the estimation of HBV replication 
(AIII). Drugs like tenofovir ,emtricitabine and lamivudine will be having action 
against both HIV infection and HBV infection.Treatment for HBV orHIV if 
needed, then ART must be commenced with  combination of TDF + FTC or 
with TDF + 3TC since there is nucleoside reverse transcriptase inhibitor 
(NRTI) backbone for a complete suppressive ART  (AI).  
When TDF cannot be used safely and HBV treatment is required then the alter-
native HBV therapy recommended is entecavir along with the completely sup-
pressive ART combination (BI).Drugs for the treatment of HBV infection in-
cludes peg interferon alpha monotherapy or 3TC in combination with adefovir 
or telbivudine or else FTC along with the completely suppressive ART (BII).  
Entecavir can be used along with the completely suppressive antiretroviral 
treatment regimen in HIV and HBV co infected individuals (AII), because en-
tecavir when used without ART drugs for HBV infection,it leads to M184V 
mutation which will raise HIV resistance 3TC and also to FTC. Hence discon-
tinuation of drugs with anti-HBV activity can cause very serious hepatocellular 
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injury resulting from reactivation of HBV.Thus patients should be advised 
against self-discontinuation and should be carefully monitored during interrup-
tions in HBV treatment (AII).  
If ART needs to be modified due to HIV virological failure and the patient has 
adequate HBV suppression, the ARV drugs active against HBV should be con-
tinued for HBV treatment in combination with other suitable ARV agents to 
achieve HIV suppression (AIII).  
HIV AND HEPATITIS C VIRUS CO INFECTION  
Every HIV infected individuals must be screened routinely for hepatitis C virus 
(HCV) infection. Individuals at risk must be screened once in a year and also 
screened whenever HCV infection is in doubt.  
Antiretroviral treatment can slowdown the liver disease progression by main-
taining the immune capacity and decreasing the HIV mediated immune activa-
tion and process of inflammation. In majority of the HIV and HCV-co infected 
patients, the benefit of antiretroviral therapy outweighs concerns regarding 
drug induced liver injury even in those with cirrhosis. Hence antiretroviral 
treatment should be started in HIV and HCV-co infected patients, irrespective 
of absolute CD4 cell counts (BII).  
 Antiretroviral treatment regimens advised for most HIV and HCV-coinfected 
patients are same as those recommended for individuals without HCV infec-
tion. But, when   treatment for both the infection are indicated, the antiretrovir-
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al treatment should be decided based on the potential drug interactions and 
their toxicities with HCV treatment combination. 
Combined treatment of HIV and HCV will lead onto complications due to drug 
interactions. But still ART should be started in most HIV/HCV co infected pa-
tients irrespective of their absolute CD4 counts, in treatment naive patients with 
absolute CD4 cell counts more than 500 cells/mm few physician may choose to 
start antiretroviral therapy later until HCV treatment gets completed (CIII).  
In patients with lower CD4 cell counts like <200 cells/ cubic mm,the antiretro-
viral therapy should be initiated promptly (AI) and treatment for HCV must be 
delayed until the patient is stable with HIV treatment (CIII).  
MYCOBACTERIUM TUBERCULOSIS DISEASE WITH HIV COIN-
FECTION  
Principles for treatment of active tuberculosis disease in HIV infected individu-
als are the same as those for HIV uninfected individuals (AI).  
In all HIV infected individuals with active TB infection should be started on 
TB treatment immediately following diagnosis (AI). All HIV infected individ-
uals with active TB infection should be treated with antiretroviral therapy 
(ART) (AI).  
In individuals with CD4 counts less than 50 cells/ cubic mm, ART should be 
started within 2 weeks of starting anti tuberculosis treatment (AI).  
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In individuals with absolute CD4 counts more than 50 cells/ cubicmmwho 
present with severe clinical disease like low Karnofsky score, low BMI, low 
albumin,low hemoglobin, organ system dysfunction, or the extent of the dis-
ease.Antiretroviral therapy should be started within 2 to 4 weeks of starting 
ATT. Strength of this recommendation varies according to the absolute CD4 
cell counts:  
 for absolute CD4 count 50 to 200 cells/ cubic mm (BI) 
 for absolute CD4 count >200 cells/ cubic mm (BIII) 
In patients with CD4 counts ≥50 cells/ cubic mmwho do not have severe clini-
cal disease, ART can be delayed beyond 2 to 4 weeks of starting TB therapy 
but should be started within 8 to 12 weeks of ATT initiation. The strength of 
this recommendation also varies on the basis of absolute CD4 cell counts 
 CD4 count 50 to 500 cells/ cubic mm
 
(AI)  
 CD4 count >500 cells/cubic mm
 
(BIII) 
In all HIV-infected pregnant women with active TB, ART should be started as 
early as possible, both for maternal health and for prevention of mother-to-
child transmission of HIV (AIII). In HIV patients with documented multidrug-
resistant (MDR) and extensively drug-resistant (XDR) TB, antiretroviral thera-
py should be started within 2 to 4 weeks of confirmation of TB drug resistance 
and initiation of second-line tuberculosis therapy (BIII).  
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Even there are pharmacokinetic drug interactions, rifamycin that is rifampin or 
rifabutin should be added in TB regimens for patients who is on ART,with do-
sage adjustment if needed (AII).  
In HIV-infected patients with active tuberculosis disease who is on a protease 
inhibitor based regimen rifabutin is preferred over rifampin due to drug interac-
tions (AII). But co-administration of rifampin and PIs with or without ritonavir 
boosting is not recommended by the panel (AII).IRIS, immune reconstitution 
inflammatory syndrome can occur after starting ART. But both ART and TB 
treatment has to be continued while managing IRIS (AIII). 
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RESULTS 
This study mainly aimed at viewing the haematological abnormalities ongoing 
in HIV infection and the impaction of these abnormalities in viral markers like 
absolute CD4 count and HIV viral load. We were successfully able to complete 
the study among 100 HIV infected individuals attending in our hospital. It was 
a cross sectional study done among both outpatient and in inpatients with their 
consent. The protocol mentioned earlier was followed in all the patients. Statis-
tical analysis of the study were given   below: 
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TABLE 1: 
HAEMOGLOBIN COUNT VS ABSOLUTE CD4 COUNT 
 ABSOLUTE CD4 COUNT 
HAEMOGLOBIN 
COUNT 
>500  
Cells / µl 
200-500 
Cells / µl 
<200 
Cells / µl 
P value 
>12 GM/DL 21 (39.6%) 14 (26.4%) 18 (34.0%)  
 
0.004 
10-12 GM/DL 5 (22.7%) 4 (18.2%) 13 (59.1%) 
8-10 GM/DL 0 (0%) 3 (16.7%) 15 (83.3%) 
<8 GM/DL 0 (0%) 2 (28.6%) 5 (71.4%) 
 
FIGURE 1: 
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TABLE 2: 
HAEMOGLOBIN COUNT VS HIV VIRAL LOAD 
 HIV VIRAL LOAD 
HAEMOGLOBIN 
COUNT 
<200 cop-
ies/ml 
200-1000 
copies/ml 
>1000 cop-
ies/ml 
P value 
>12 GM/DL 38 (71.7%) 1 (1.9%) 14 (26.4%)  
 
0.000 
10-12 GM/DL 9 (40.9%) 0 (0%) 13 (59.1%) 
8-10 GM/DL 1(5.6%) 0 (0%) 17 (94.4%) 
<8 GM/DL 0 (0%) 1 (14.3%) 6 (85.7%) 
 
FIGURE 2: 
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ANAEMIA 
In this study there were significant association noted between low haemoglobin 
count and absolute CD4 count and HIV viral load. Individuals with high viral 
load and low CD4 count < 200 cells/ microlitre had higher prevalence of anae-
mia. Severe anaemia was noted about 71.4% among CD 4 count < 200 cells/ 
microlitre, 28.6% among CD 4 count 200-500 cells/ microlitre and about 26% 
among CD 4 count >500 cells/ microlitre, as shown in Table 1.Severe anaemia 
was noted about 85.7% among HIV viral load >1000 copies/ ml, as  shown in 
Table 2. Statistical analysis showed signicant P value among haemoglobin 
count and absolute CD4 count of 0.004 and with HIV viral load, P value was 
about 0.000. 
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TABLE 3: 
HAEMOGLOBIN COUNT VS ABSOLUTE CD4 COUNT 
(in treatment naive patients) 
 ABSOLUTE CD4 COUNT 
HAEMOGLOBIN 
COUNT 
(naive patients) 
>500 
cells/ µl 
200-500 
cells/ µl 
 
<200 
cells/ µl 
P value 
>12 GM/DL 17 (39.5%) 13 (30.2%) 13 (30.2%)  
 
0.008 
10-12 GM/DL 3 (15.8%) 3 (15.8%) 13 (68.4%) 
8-10 GM/DL 0 (0%) 3 (23.1%) 10 (76.9%) 
<8 GM/DL 0 (0%) 2 (33.3%) 4 (66.7%) 
 
FIGURE 3: 
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TABLE 4: 
HAEMOGLOBIN COUNT VS HIV VIRAL LOAD 
(in treatment naive patients) 
 HIV VIRAL LOAD 
HAEMOGLOBIN 
COUNT 
(naive patients) 
<200 cop-
ies/ml 
200-1000 
copies/ml 
>1000 cop-
ies/ml 
P value 
>12 GM/DL 29 (67.4%) 1 (2.3%) 13 (30.2%)  
 
0.000 
10-12 GM/DL 6 (31.6%) 0 (0%) 13 (68.4%) 
8-10 GM/DL 0 (0%) 0 (0%) 13 (100.0%) 
<8 GM/DL 0 (0%) 1 (16.7%) 5 (83.3%) 
 
FIGURE 4: 
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 In this study there were 81 treatment naïve individuals. So that statistical anal-
ysis were done separately among naïve patients. Treatment naïve individuals 
with high viral load and low CD4 count < 200 cells/ micro litre had higher pre-
valence of anaemia. Severe anaemia was noted about 66.7% among CD 4 count 
< 200 cells/ microlitre, 33.3% among CD 4 count 200-500 cells/ microlitre and 
about 0% among CD 4 count >500 cells/ microlitre,as shown in Table 3. Se-
vere anaemia was noted about 83.3% among HIV viral load  >1000 copies/ ml 
and 0 % among HIV viral load <200 copies/ ml, as shown in Table 4.Statistical 
analysis showed signicant p value among haemoglobin count in treatment naïve 
patients and absolute CD4 count of  about 0.008 and with HIV viral load P val-
ue was about 0.000. 
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TABLE 5: 
PLATELET COUNT VS ABSOLUTE CD4 COUNT 
 ABSOLUTE CD4 COUNT 
PLATELET 
COUNT 
>500 
cells/ µl 
200-500 
cells /µl 
<200 
cells/ µl 
P value 
50000-100000 /µl 26 (27.7%) 22 (23.4%) 46 (48.9%)  
0.511 
20000-50000/ µl 0 (0%) 0 (0%) 1 (100.0%) 
<20000/ µl 0 (0%) 1 (20%) 4 (80.0%) 
 
FIGURE 5: 
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TABLE 6: 
PLATELET COUNT VS ABSOLUTE CD4 COUNT 
( in treatment naive patients) 
 ABSOLUTE CD4 COUNT 
PLATELET 
COUNT 
( naive patients) 
>500 
cells/ µl 
200-500 
cells /µl 
<200 
cells/ µl 
P value 
50000-100000 /µl 20 (25.0%) 21 (26.3%) 39 (48.8%)  
0.595 
20000-50000/ µl 0 (0%) 0 (0%) 0 (0%) 
<20000/ µl 0 (0%) 0 (0%) 1 (100.0%) 
 
FIGURE 6: 
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TABLE 7: 
PLATELET VS HIV VIRAL LOAD 
 HIV VIRAL LOAD 
PLATELET 
COUNT 
<200 cop-
ies/ml 
200-1000 cop-
ies/ml 
>1000 cop-
ies/ml 
P  
value 
50000-100000 / µl 47 (50.0%) 2 (2.1%) 45 (47.9%)  
0.560 
20000-50000/ µl 0 (0%) 0 (0%) 1 (100.0%) 
<20000/ µl 1 (20.0%) 0 (0%) 4 (80.0%) 
 
FIGURE 7: 
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TABLE 8: 
PLATELET COUNT VS HIV VIRAL LOAD 
(in treatment naive patient) 
 HIV VIRAL LOAD 
PLATELET 
COUNT 
(naive patient) 
<200 cop-
ies/ml 
200-1000 cop-
ies/ml 
>1000 cop-
ies/ml 
P 
value 
50000-100000 / µl 35 (43.8%) 2 (2.5%) 43 (53.8%)  
0.653 
20000-50000/ µl 0 (0%) 0 (0%) 0 (0%) 
<20000/ µl 0 (0%) 0 (0%) 1 (100.0%) 
 
FIGURE 8: 
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Among total samples, analysis of platelet count and absolute CD4 count shows 
a p value of 0.511 (Table 5) and in treatment naïve patients was 0.595 (Table 
6), which were insignificantly associated . 
Comparison of platelet count and HIV viral load shows a p value of 0.560 (Ta-
ble 7) and in treatment naïve patients was 0.653 (Table 8), which were insigni-
ficant . 
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TABLE 9: 
ABSOLUTE NEUTROPHIL COUNT VS ABSOLUTE CD4 COUNT 
 ABSOLUTE CD4 COUNT 
ABSOLUTE 
NEUTROPHIL 
COUNT 
>500 
cells/ µl 
200-500 
cells/ µl 
<200 
cells/ µl 
P VALUE 
1000-1500 / µl 26 (28.3%) 22 (23.9%) 44 (47.8%)  
0.266 
500-1000/ µl 0 (0%) 1 (16.7%) 5 (83.3%) 
<500/ µl 0 (0%) 0 (0%) 2 (100.0%) 
 
FIGURE 9: 
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TABLE 10: 
ABSOLUTE NEUTROPHIL COUNT VS ABSOLUTE CD4 COUNT 
(In treatment naive patient) 
 ABSOLUTE CD4 COUNT 
ABSOLUTE 
NEUTROPHIL 
COUNT 
(naïve patient) 
>500 
cells/ µl 
200-500 
cells/ µl 
 
<200 
cells/ µl 
 
P Value 
1000-1500 / µl 20 (27.0%) 20 (27.0%) 34 (45.9%)  
0.345 
500-1000/ µl 0 (0%) 1 (16.7%) 5 (83.3%) 
<500/ µl 0 (0%) 0 (0%) 1 (100.0%) 
 
FIGURE 10:
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TABLE 11: 
ABSOLUTE NEUTROPHIL COUNT VS HIV VIRAL LOAD 
 HIV VIRAL LOAD 
ABSOLUTE 
NEUTROPHIL 
COUNT 
<200 cop-
ies/ml 
200-1000 
copies/ml 
>1000 cop-
ies/ml 
P value 
1000-1500 / µl 48 (52.2%) 2 (2.2%) 42 (45.7%)  
0.069 
500-1000/ µl 0 (0%) 0 (0%) 6 (100.0%) 
<500/ µl 0 (0%) 0 (0%) 2 (100.0%) 
  
FIGURE 11: 
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TABLE 12 : 
ABSOLUTE NEUTROPHIL COUNT VS HIV VIRAL LOAD 
(in treatment naïve patient) 
 HIV VIRAL LOAD 
ABSOLUTE 
NEUTROPHIL 
COUNT 
<200 cop-
ies/ml 
200-1000 
copies/ml 
>1000 cop-
ies/ml 
P value 
1000-1500 / µl 35(47.3%) 2 (2.7%) 37 (50.0%)  
0.168 
500-1000/ µl 0 (0%) 0 (0%) 6 (100.0%) 
<500/ µl 0 (0%) 0 (0%) 1 (100.0%) 
 
FIGURE 12:
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Among total samples, analysis of absolute neutrophil count and absolute CD4 
count shows a p value of 0.266 (Table 9) and in treatment naïve patients was 
0.345 (Table 10), which were insignificantly associated. 
Comparison of absolute neutrophil count and HIV viral load shows a p value of 
0.069 (Table 11) and in treatment naïve patients was 0.168 (Table 12), which 
were insignificant. 
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TABLE 13: 
TYPE OF ANAEMIA AMONG NAIVE PATIENTS 
NORMAL 43 (53.1%) 
ANAEMIA OF CHRONIC DISEASE 29 (35.8%) 
IRON DEFICIENCY ANAEMIA 7 (8.6%) 
VITAMIN B12 DEFICIENCY ANAEMIA 2 (2.5%) 
HEMOLYTIC ANAEMIA 0 (0%) 
 
FIGURE 13: 
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TYPE OF ANAEMIA: 
In this study, normocytic normochromic blood picture was noted in majority of 
the patients, as shown in Table 13. Among the type of anaemia, anaemia of 
chronic disease blood picture was more prevalent among these individuals. It 
was about 35.8 % among the total cases. Iron deficiency anaemia was noted 
about 8.6% of the cases. Vitamin B12 deficiency was documented in 2% of the 
case. Hemolytic anaemia was not noted in this study. 
TABLE 14: 
ABSOLUTE CD4 COUNT VS COINFECTION 
ABSOLUTE CD4 
COUNT 
CO-INFECTION 
ABSENT 
CO-INFECTION 
PRESENT 
P VALUE 
>500 cells/ µl 22 (84.6%) 4 (15.4%)  
0.000 200-500 cells/µl 1 (47.8%) 12 (52.2%) 
<200 cells/ µl 8 (16.0%) 42 (84.0%) 
 
FIGURE 14: 
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TABLE 15:          HIV VIRAL LOAD VS CO INFECTION 
HIV VIRAL LOAD CO-INFECTION 
ABSENT 
CO-INFECTION 
PRESENT 
P  
Value 
<200 copies/ml 34 (70.8%) 14 (29.2%) 0.000 
200-1000 copies/ml 2 (100.0%) 0 (0%) 
>1000 copies/ml 5 (10.0%) 45 (90.0%) 
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TABLE 16: 
CO INFECTIONS 
S.NO TYPE OF INFECTION FREQUENCY PERCENTAGE 
1 PULMONARY TUBERCULOSIS 25 25 
2 EXTRAPULMONARY TUBER-
CULOSIS 
11 11 
3 ORAL CANDIDIASIS 8 8 
4 CEREBRAL TOXOPLASMOSIS 4 4 
5 OESOPHAGEAL CANDIDIASIS 5 5 
6  MALIGNANCY 2 2 
7 PNEUMOCYSTIS JIROVECI 2 2 
8 HEPATITIS B COINFECTION 2 2 
9  NOCARDIASIS 1 1 
10 ACUTE PANCREATITIS  3 3 
11 HERPES SIMPLEX INFECTION 1 1 
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FIGURE 16: 
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COINFECTION  
Comparison of occurrence of co infection and absolute CD4 count showed a p 
value of 0.000 (Table 14) and comparison of occurrence of co infection and 
HIV viral load showed a p value of 0.000 (Table 15). There were significant 
association noted between the occurrence of co infection and absolute CD4 
count and HIV viral load. In individuals with high viral load and low CD4 
count < 200 cells/ micro litre had higher rate of occurrence of co infection. 
 Among the co infections pulmonary tuberculosis were predominant and it was 
about 25% of the total. Extrapulmonary tuberculosis were noted about 11%. 
CNS toxoplasmosis were noted among 4 individuals. Oral candidiasis were 
about 8% and oesophageal candidiasis were about 5%. Other co infections 
noted were pneumocystis jiroveci infection, nocardiasis, herpes simplex infec-
tion.All were about less than 5%. Malignancies and hepatitis B co infection 
were noted about 2 % of the total population. Acute pancreatitis were noted 
about 3 % of the cases.  
BONE MARROW BIOPSY: 
In this study, bone marrow biopsy was done among 5 patients. Among 3 indi-
viduals , the bone marrow picture was erythroid hyperplasia with mild dyseryt-
hropoiesis, megakaryocytic hyperplasia and mild increase in plasma cells 
which were suggestive of HIV infection. In 2 of the individuals, immune 
thrombocytopenia were considered. 
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Nearly 10 patients had pancytopenia picture. In this study about 81 patients 
were treatment naïve and 19 were on anti retroviral therapy. Among the indi-
viduals on anti retroviral therapy,those patients who were on zidovudine based 
therapy were having normocytic normochromic anaemia with macrocytosis. 
  
76 | P a g e  
 
DISCUSSION 
This study among HIV infected individuals from South India showed preva-
lence of anaemia about 47% as compared to Mildvan et alwho found the preva-
lence of anemia in 9690 HIV infected patients as 39.5%. In this study, anaemia 
was more prevalent in individuals with high HIV viral load and low absolute 
CD4 count .This was the same like many studies quoted in the literature re-
view. Even the severity of anaemia was significantly correlated with high HIV 
viral load and low absolute CD4 count. These findings are consistent with 
study done by Volberding et al., who reported that more severe levels of ane-
mia are found among HIV positive patients presenting with low CD4 counts. 
Among the total cases, anaemia was more common than thrombocytopenia or 
neutropenia.In treatment naïve individuals and individuals on ART, thrombo-
cytopenia and neutropenia were more prevalent among high HIV viral load and 
low CD4 count < 200 cells/ microlitre. But statistical analysis showed insigni-
cant P value in both the groups.  
The incidence and severity of anaemia, thrombocytopenia and neutropenia 
were reflecting the underlying immune status if interpreted cautiously. It will 
be of great benefit especially if the patient is in regular follow-up. Hence it is 
necessary to identify and treat for hematological abnormalities to reduce the 
morbidity and mortality. 
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CONCLUSION 
Though there were many studies been conducted across India on HIV manife-
stations, in majority of them, various aspects were addressed and the prime fo-
cus on the hematological manifestations were very limited. Most of the availa-
ble data what we presently have is from the western studies, which might not 
be directly applicable to our Indian population. Hence this study was planned 
and done in Indian population mainly from South India. This study looked into 
the hematological manifestations and their correlation with viral markers. 
HIV viral load and absolute CD 4 count are the most essential biomarkers cor-
relating to the stage of HIV disease and its progression. But these tests are cos-
tlier. Even developed nations were finding it difficult. So country like ours def-
initely requires other alternatives to reduce the economical burden by frequent 
testing. For the sake of economical evaluation of the status of HIV disease 
stage and its progression, complete blood counts and peripheral smear has been 
suggested as the alternatives, since they were significantly correlated with high 
HIV viral load and lower absolute CD4 cell counts.  
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topic: :  
Profile of hematological abnormalities and its correlation with absolute CD4 
count and HIV viral load in HIV infected patients in a tertiary care hospital  
as part of my / our research project being carried out under the aegis of the Department 
of: General medicine 
(Applicable to students only): My / our research guide is: Dr. T.Saravanan MD. 
The justification for this study is:  
Though many studies have been conducted on various manifestations of HIV disease, the 
focus  on hematological abnormalities in these studies is very little. Also there are very 
few literature in Indian population correlating hematological abnormalities to absolute 
CD4 count , HIV viral load  and opportunistic infections. Most of the available data is 
from the west, which might not be directly applicable to our Indian population.Therefore 
this study would evaluate the correlation in HIV to absolute CD4 count and viral load.  
Ojectives of the study are:  
Primary objective:  
   To study the spectrum of hematological abnormalities in HIV infected patients 
Secondary objective:  
   To find the correlation of hematological abnormalities with absolute CD4 count 
and HIV viral load 
Sample size: 100 
Study volunteers / participants are (specify population group & age group): patients 
above age of 16 years who have been diagnosed of HIV infection either by ELISA or 
western blot method.  
Location: PSG hospitals , Coimbatore.  
Data collected will be stored for a period of three years. We will / will not use the data as 
part of another study. 
Blood sample collection: Specify quantity of blood being drawn: __10__ml.  
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Benefits from this study:  .Effective treatment to bring down the morbidity and mortality 
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thesis in post graduate course in general medicine.  
If you are uncomfortable in answering any of our questions during the course of the 
interview / biological sample collection, you have the right to withdraw from the 
interview / study at anytime. You have the freedom to withdraw from the study at any 
point of time. Kindly be assured that your refusal to participate or withdrawal at any 
stage, if you so decide, will not result in any form of compromise or discrimination in the 
services offered nor would it attract any penalty. You will continue to have access to the 
regular services offered to a patient. You will NOT be paid any remuneration for the time 
you spend with us for this interview / study. The information provided by you will be 
kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any significant new 
findings- including adverse events, if any, – whether directly related to you or to other 
participants of this study, developed during the course of this research which may relate 
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MASTER CHART KEY 
 
HAEMOGLOBIN COUNT 
1 NORMAL          >12 GM/DL 
2 MILD                 10-12 GM/DL 
3 MODERATE      8-10 GM/DL 
4 SEVERE            <8 GM/DL 
 
PLATELET COUNT 
THROMBOCYTOPENIA   
1  MILD                          50000-100000/ µl 
2  MODERATE              20000-50000/ µl  
3  SEVERE                      <20000 / µl 
 
 
ABSOLUTE NEUTROPHIL COUNT 
1 MILD NEUTROPENIA 1000-1500/ µl 
2 MODERATE 500-1000/ µl 
3 SEVERE <500/ µl 
 
 
TYPE OF ANAEMIA 
1 NORMAL 
2 ANAEMIA OF CHRONIC DISEASE 
3 IRON DEFICIENCY ANAEMIA 
4 VITAMIN B12 DEFICIENCY ANAEMIA 
5  HEMOLYTIC ANAEMIA 
 
ABSOLUTE CD4 COUNT 
1  -      >500 CELS/  µl 
2  -      200-500 CELS/  µl 
3  -     <200 CELS/  µl 
 HIV RNA VIRAL LOAD 
1  -   <200 COPIES/ML 
2  -    200-1000 COPIES/ML 
3 -     >1000 COPIES/ML 
 
 
 BONE MARROW PICTURE  
 
1-Erythroid hyperplasia with mild dyserythropoiesis, megakaryocytic hyperplasia and 
mild increase in plasma cells  
2- Immune thrombocytopenia 
 
 
